Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MDCI > SEC Filings for MDCI > Form 8-K on 17-Jul-2013All Recent SEC Filings




Change in Directors or Principal Officers, Financial Statements and

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 12, 2013, Mr. John Sheffield entered into a separation agreement (the "Separation Agreement") with Medical Action Industries Inc. (the "Company"). Mr. Sheffield had recently resigned as Executive Vice President, Chief Financial Officer and Corporate Secretary of the Company, as reported in the Company's Current Report on Form 8-K dated June 28, 2013 (the "Resignation Date").

The Separation Agreement provides that Mr. Sheffield will be reasonably available to the Company to respond to questions relative to matters he was working on at the Company, at no additional expense to the Company, from the Resignation Date until December 27, 2013 (such period, the "Severance Period"), except for necessary out-of-pocket expenses actually incurred with the Company's prior approval. Pursuant to the Separation Agreement, Mr. Sheffield returned to the Company, on or before July 12, 2013, all Company files, manuals, reports and other documents and property of the Company in Mr. Sheffield's possession and provided the chief executive officer of the Company with a document describing all outstanding business issues Mr. Sheffield worked on as of the Resignation Date. Mr. Sheffield also agreed to waive any actions of any kind against the Company and to keep confidential and not disclose to any third party (including any competitor) any confidential information about the Company's business.

For a period of six months following the Resignation Date, Mr. Sheffield will not:

Accept employment with, provide advice, consulting services, or in any other capacity work for or provide services to companies that directly compete with the Company; nor

Solicit or service orders for the purchase of products similar to those manufactured/sold by the Company to any person, firm, or entity which was a customer or prospective customer of the Company or to whom Mr. Sheffield solicited or serviced orders on behalf of the Company during one year preceding the Resignation Date.

For twelve months following the Resignation Date, Mr. Sheffield will not directly or indirectly, hire, solicit or attempt to hire any employee of the Company to leave the Company's employ or to cause any new employee of the Company to become employed in any business which is competitive with the Company.

In consideration of the services provided by Mr. Sheffield after the Resignation Date and expected to be provided by Mr. Sheffield during the Severance Period and Mr. Sheffield's other agreements under the Separation Agreement, Mr. Sheffield shall continue to receive from the Company during the Severance Period, a bi-weekly salary in the amount of $11,538.46, less standard legal deductions. The Company also agreed to continue paying, during the Severance Period, Mr. Sheffield's bi-weekly automobile allowance of $576.92 and to reimburse, during the Severance Period, Mr. Sheffield for COBRA healthcare coverage.

If, during the Severance Period, Mr. Sheffield commences new employment ("New Employment"), (i) the Company shall cease making all payments to Mr. Sheffield under the Separation Agreement, (ii) Mr. Sheffield's entitlement to benefits reimbursement shall end, (iii) Mr. Sheffield's obligations to provide business assistance to the Company shall end and (iv) the Company shall have no further obligation to provide Mr. Sheffield with further payments or benefits of any kind thereafter, even if Mr. Sheffield should again become unemployed. Notwithstanding the foregoing, should Mr. Sheffield's New Employment be at a lesser salary than his final, bi-weekly salary at the Company of $11,538.46, the Company shall continue making payments for the remainder of the Severance Period in an amount equal to that difference.

The foregoing summary of the Separation Agreement is qualified in its entirety by reference to the full text of the Separation Agreement, which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibits are attached to this Current Report on Form 8-K:

Exhibit No                 Description of Exhibit
10.1       Separation Agreement, entered into on July 12, 2013,
           by and between Medical Action Industries Inc. and John

  Add MDCI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MDCI - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.